CHARLES SCHWAB INVESTMENT MANAGEMENT INC - ARCUTIS BIOTHERAPEUTICS INC ownership

ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of ARCUTIS BIOTHERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,038,047
-35.2%
383,813
+16.3%
0.00%0.0%
Q2 2023$3,144,347
-5.5%
329,942
+9.1%
0.00%0.0%
Q1 2023$3,327,522
-25.5%
302,502
+0.3%
0.00%0.0%
Q4 2022$4,465,574
-19.7%
301,728
+3.7%
0.00%
-50.0%
Q3 2022$5,563,000
+20.2%
291,093
+34.0%
0.00%0.0%
Q2 2022$4,630,000
+19.6%
217,260
+8.1%
0.00%
+100.0%
Q1 2022$3,871,000
-6.0%
200,964
+1.3%
0.00%0.0%
Q4 2021$4,116,000
-12.0%
198,453
+1.3%
0.00%
-50.0%
Q3 2021$4,679,000
-11.3%
195,837
+1.3%
0.00%0.0%
Q2 2021$5,278,000
+1.5%
193,382
+7.6%
0.00%0.0%
Q1 2021$5,199,000
+30.7%
179,680
+27.0%
0.00%0.0%
Q4 2020$3,979,000
+22.7%
141,439
+27.9%
0.00%
+100.0%
Q3 2020$3,242,000
+57.1%
110,623
+62.1%
0.00%0.0%
Q2 2020$2,064,000
+214.2%
68,246
+209.9%
0.00%
Q1 2020$657,00022,0210.00%
Other shareholders
ARCUTIS BIOTHERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Frazier Life Sciences Management, L.P. 8,684,232$165,956,00012.78%
Bain Capital Life Sciences Investors, LLC 3,000,000$57,330,0006.84%
Pivotal bioVenture Partners Investment Advisor LLC 569,041$10,874,0003.97%
Logos Global Management LP 1,525,000$29,143,0003.58%
1492 Capital Management LLC 178,320$3,408,0002.45%
Cormorant Asset Management, LP 1,000,000$19,110,0001.34%
MPM BioImpact LLC 257,185$4,915,0001.16%
Orbimed Advisors 2,800,000$53,508,0000.99%
SECTORAL ASSET MANAGEMENT INC 220,985$4,223,0000.83%
Rubric Capital Management LP 472,047$9,021,0000.45%
View complete list of ARCUTIS BIOTHERAPEUTICS INC shareholders